140 related articles for article (PubMed ID: 11010833)
1. Reduction of side effects of intravesical therapy with bacille Calmette-Guérin by pentoxifylline?--an in vitro approach.
Böhle A; Thanhäuser A; Ernst M; Flad HD; Rüsch-Gerdes S; Jocham D; Ulmer AJ
Clin Infect Dis; 2000 Sep; 31 Suppl 3():S101-5. PubMed ID: 11010833
[TBL] [Abstract][Full Text] [Related]
2. In vitro generation of bacillus Calmette-Guérin-activated killer cells.
Brandau S; Böhle A; Thanhäuser A; Ernst M; Mattern T; Ulmer AJ; Flad HD
Clin Infect Dis; 2000 Sep; 31 Suppl 3():S94-S100. PubMed ID: 11010832
[TBL] [Abstract][Full Text] [Related]
3. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells.
Brandau S; Suttmann H; Riemensberger J; Seitzer U; Arnold J; Durek C; Jocham D; Flad HD; Böhle A
Clin Cancer Res; 2000 Sep; 6(9):3729-38. PubMed ID: 10999767
[TBL] [Abstract][Full Text] [Related]
4. Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2.
Yamada H; Matsumoto S; Matsumoto T; Yamada T; Yamashita U
J Urol; 2000 Aug; 164(2):526-31. PubMed ID: 10893638
[TBL] [Abstract][Full Text] [Related]
5. Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49).
Günther JH; Frambach M; Deinert I; Brandau S; Jocham D; Böhle A
J Urol; 1999 May; 161(5):1702-6. PubMed ID: 10210443
[TBL] [Abstract][Full Text] [Related]
6. Intravesical bacille Calmette-Guérin induces the antiangiogenic chemokine interferon-inducible protein 10.
Poppas DP; Pavlovich CP; Folkman J; Voest EE; Chen X; Luster AD; O'Donnell MA
Urology; 1998 Aug; 52(2):268-75; discussion 275-6. PubMed ID: 9697793
[TBL] [Abstract][Full Text] [Related]
7. Pentoxifylline: a potent inhibitor of IL-2 and IFN-gamma biosynthesis and BCG-induced cytotoxicity.
Thanhäuser A; Reiling N; Böhle A; Toellner KM; Duchrow M; Scheel D; Schlüter C; Ernst M; Flad HD; Ulmer AJ
Immunology; 1993 Sep; 80(1):151-6. PubMed ID: 8244458
[TBL] [Abstract][Full Text] [Related]
8. Immunodominant PstS1 antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer.
Sänger C; Busche A; Bentien G; Spallek R; Jonas F; Böhle A; Singh M; Brandau S
BMC Cancer; 2004 Nov; 4():86. PubMed ID: 15566565
[TBL] [Abstract][Full Text] [Related]
9. Treatment of bladder carcinomas using recombinant BCG DNA vaccines and electroporative gene immunotherapy.
Lee CF; Chang SY; Hsieh DS; Yu DS
Cancer Gene Ther; 2004 Mar; 11(3):194-207. PubMed ID: 14973549
[TBL] [Abstract][Full Text] [Related]
10. Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guérin.
O'Donnell MA; Luo Y; Chen X; Szilvasi A; Hunter SE; Clinton SK
J Immunol; 1999 Oct; 163(8):4246-52. PubMed ID: 10510362
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer.
Lamm DL
Clin Infect Dis; 2000 Sep; 31 Suppl 3():S86-90. PubMed ID: 11010830
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms.
Prescott S; Jackson AM; Hawkyard SJ; Alexandroff AB; James K
Clin Infect Dis; 2000 Sep; 31 Suppl 3():S91-3. PubMed ID: 11010831
[TBL] [Abstract][Full Text] [Related]
13. Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy.
Gallagher BL; Joudi FN; Maymí JL; O'Donnell MA
Urology; 2008 Feb; 71(2):297-301. PubMed ID: 18308107
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer.
Yu DS; Lee CF; Hsieh DS; Chang SY
Urology; 2004 Mar; 63(3):596-601. PubMed ID: 15028475
[TBL] [Abstract][Full Text] [Related]
15. Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response.
De Boer EC; Rooijakkers SJ; Schamhart DH; Kurth KH
J Urol; 2003 Nov; 170(5):2004-8. PubMed ID: 14532842
[TBL] [Abstract][Full Text] [Related]
16. Dissecting the immunobiological effects of Bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon.
Böhle A; Thanhäuser A; Ulmer AJ; Ernst M; Flad HD; Jocham D
J Urol; 1993 Dec; 150(6):1932-7. PubMed ID: 8230540
[TBL] [Abstract][Full Text] [Related]
17. Significance of target cell infection and natural killer cells in the anti-tumor effects of bacillus Calmette-Guerin in murine bladder cancer.
Sonoda T; Sugimura K; Ikemoto S; Kawashima H; Nakatani T
Oncol Rep; 2007 Jun; 17(6):1469-74. PubMed ID: 17487406
[TBL] [Abstract][Full Text] [Related]
18. Bladder contracture: review for intravesical bacillus Calmette-Guerin complication.
Hameed A; Sezian N; Thwaini A
Can J Urol; 2007 Dec; 14(6):3745-9. PubMed ID: 18163926
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of natural, interleukin-2 stimulated and bacillus Calmette-Guerin enhanced cytotoxicity with anti-CD16 antibodies.
Kaasinen ES; Harju LM; Timonen TT
J Urol; 2002 May; 167(5):2209-14. PubMed ID: 11956480
[TBL] [Abstract][Full Text] [Related]
20. What are the immunologically active components of bacille Calmette-Guérin in therapy of superficial bladder cancer?
Zlotta AR; Van Vooren JP; Denis O; Drowart A; Daffé M; Lefèvre P; Schandene L; De Cock M; De Bruyn J; Vandenbussche P; Jurion F; Palfliet K; Simon J; Schulman CC; Content J; Huygen K
Int J Cancer; 2000 Sep; 87(6):844-52. PubMed ID: 10956396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]